Akari Therapeutics plc ADR (0.01 USD) (AKTX)

Akari Therapeutics has successfully completed the merger with Peak Bio, creating an innovative biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The combined entity secured $3.2 million in PIPE financing and a $50 million term sheet for an equity line of credit to support its pipeline development.

Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024

Penny stocks to watch before next week. The post Best Penny Stocks To Buy? 6 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Apellis' (APLS) recently approved drug, Empaveli, demonstrates superiority in hemoglobin stabilization and reduction in LDH level in treatment-naive PNH patients.